Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab with Chemotherapy for Pediatric Rhabdomyosarcoma
NCT06456892Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in rhabdomyosarcoma (RMS), sponsored by Sun Yat-sen University. Primary endpoints: Dose-Limiting Toxicity at 28 days and Pathological Complete Response. Started Jun 2024; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT06456892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456892.